Myeloid leukemia

Results: 723



#Item
91Tyler Vestal, Columbia University College of Physicians and Surgeons    It took nearly 13 years and cost over $3 billion to sequence the human genome for the first time, a task that  was 

Tyler Vestal, Columbia University College of Physicians and Surgeons    It took nearly 13 years and cost over $3 billion to sequence the human genome for the first time, a task that  was 

Add to Reading List

Source URL: blog.23andme.com

Language: English - Date: 2014-04-25 14:13:55
92July 20, 2012 DACOGEN(R) Receives a Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia DUBLIN, Calif., July 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:

July 20, 2012 DACOGEN(R) Receives a Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia DUBLIN, Calif., July 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:

Add to Reading List

Source URL: astx.com

Language: English
93Critical appraisal of Prognostic studies Are the results of the study valid? (Internal Validity) 1.Was the defined representative sample of patients assembled at a common (usually early) point in the course of their dise

Critical appraisal of Prognostic studies Are the results of the study valid? (Internal Validity) 1.Was the defined representative sample of patients assembled at a common (usually early) point in the course of their dise

Add to Reading List

Source URL: www.cebm.net

Language: English - Date: 2014-06-12 06:43:06
94September 30, 2013 Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress DUBLIN, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a ph

September 30, 2013 Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress DUBLIN, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a ph

Add to Reading List

Source URL: astx.com

Language: English
95SuperGen Announces Enrollment of First Patient in First in Human Trial of SGI-110 in MDS and AML Patients DUBLIN, Calif., Jan 05, 2011 (BUSINESS WIRE) -SuperGen, Inc. (NASDAQ:SUPG) today announced that it has enrolled th

SuperGen Announces Enrollment of First Patient in First in Human Trial of SGI-110 in MDS and AML Patients DUBLIN, Calif., Jan 05, 2011 (BUSINESS WIRE) -SuperGen, Inc. (NASDAQ:SUPG) today announced that it has enrolled th

Add to Reading List

Source URL: astx.com

Language: English
96April 10, 2013 Astex Pharmaceuticals Provides SGI-110 Update Oral Presentation at AACR Supports Potential of SGI-110 In The Treatment Of Platinum-Resistant Ovarian Cancer Clinical Update on SGI[removed]Study DUBLIN, Cali

April 10, 2013 Astex Pharmaceuticals Provides SGI-110 Update Oral Presentation at AACR Supports Potential of SGI-110 In The Treatment Of Platinum-Resistant Ovarian Cancer Clinical Update on SGI[removed]Study DUBLIN, Cali

Add to Reading List

Source URL: astx.com

Language: English
97Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc

Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc

Add to Reading List

Source URL: astx.com

Language: English
98December 10, 2012 Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH DUBLIN, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceu

December 10, 2012 Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH DUBLIN, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceu

Add to Reading List

Source URL: astx.com

Language: English
99June 22, 2012 Astex Pharmaceuticals Announces Initiation of the Phase 2 Expansion of the SGI-110 Clinical Trial in MDS and AML Patients DUBLIN, Calif., June 22, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasd

June 22, 2012 Astex Pharmaceuticals Announces Initiation of the Phase 2 Expansion of the SGI-110 Clinical Trial in MDS and AML Patients DUBLIN, Calif., June 22, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasd

Add to Reading List

Source URL: astx.com

Language: English
100Astex Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the pre-publication notice of the

Astex Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the pre-publication notice of the

Add to Reading List

Source URL: astx.com

Language: English